HCB101 targets CD47 on tumor cells to relieve the SIRPα ‘don’t‑eat‑me’ signal, enabling macrophage phagocytosis; its IgG4 Fc engages FcγRs (including CD32C) on myeloid cells to enhance effector function, but it does not target or kill CD32C-expressing cells.